Switzerland: Revision of Narcotics Act – Switzerland fully legalizes medicinal cannabis

In brief

On 1 August 2022, Swiss National Day, Switzerland's revised Narcotics Act ("NarcA") entered into force. The revision aims at facilitating medical treatments and improving research and development of cannabis. Prior to the revised law, patients and physicians had to apply for special authorization from the Federal Office of Public Health (FOPH) if they wanted to access cannabis for medical purposes. The amendment will allow numerous patients safe and timely access to cannabis medicines as part of their treatment regime. This signifies a further step in modernizing Switzerland's legislation on cannabis.


According to a study by the Institute for Addiction and Health Research carried out on behalf of the FOPH, 96% of participants reported that the consumption of medicinal cannabis led to an improvement of their symptoms. In light of cannabis's potential as a medical treatment and the surge in applications and high approval rates of the FOPH in the last few years, the costly and time-consuming procedure physicians and patients had to undergo to obtain authorization for treatment with medicinal products containing cannabis was no longer justified. This led to the latest revision of the NarcA, which focuses on the legalization of medicinal cannabis, making cultivation, processing, production and trade thereof subject to the authorization procedure of Swissmedic in the same way as other narcotics that are used in a medical context.

Key takeaways

The main features of the amendment include the following:

  • Every licensed physician is now able to prescribe medicinal products containing cannabis as part of the general principle of therapeutic freedom, and special authorization by the FOPH is no longer required.
  • The cultivation, production, processing and trade of medicinal cannabis is now subject to the authorization procedure of Swissmedic.
  • A two-stage authorization procedure has been established for the cultivation of cannabis plants for medicinal purposes.


Prior to the enactment of the revised law, cannabis with tetrahydrocannabinol (THC) levels of 1% and above were classified as prohibited narcotics in Switzerland. As a result, cannabis with THC levels of 1% and above could not be cultivated, produced, imported or placed on the market. This limited the medicinal use of cannabis, which was subject to a case-by-case authorization requirement from the FOPH.

Products containing cannabis with THC levels below 1% and products containing cannabidiol (CBD) are not subject to the NarcA and therefore were not prohibited even before the revision. The use of cannabis for non-medicinal purposes, however, remains prohibited.

Removal of ban on medicinal cannabis

According to the revised NarcA, cannabis is classified as a controlled narcotic with restricted marketability. Therefore, the cultivation, production, processing and trade of medicinal cannabis will be subject to the authorization and control system of Swissmedic and a special authorization from the FOPH will thus no longer be required. The revision aims to maximize the full potential of cannabis as a medicinal product and to ease access to medicinal cannabis for physicians and patients alike.

As a result of the removal of the ban on medicinal cannabis, the following is now possible in Switzerland:

  • Licensed physicians may now prescribe medicinal products containing cannabis as part of the general principle of therapeutic freedom without the need to obtain special authorization from the FOPH.
  • Public pharmacies and hospital pharmacies that have obtained a manufacturing license for medicinal products are authorized to manufacture and dispense medicinal products with cannabis.
  • The commercial export of cannabis for medicinal purposes is now generally possible with a license from Swissmedic. This creates economic opportunities for domestic growers and specialized manufacturers of these herbal medicines.

In order to evaluate the effects of the revision, physicians are required to regularly report on medicinal cannabis-based therapies to the FOPH for the first few years after the revision of the law has taken effect The data collected will help guide cantonal enforcement authorities and prescribing physicians on further treatment using medicinal cannabis.

Reimbursement by the compulsory health insurance

As a general rule, the reimbursement of costs for medicinal products by the compulsory health insurance ("OKP") requires that the medicinal product is included in the FOPH's list of specialties ("SL"). In order for a medicinal product to be included in the SL, it is required that a marketing authorization is obtained for the medicinal product and that scientific proof of the efficacy, usefulness and cost-effectiveness of the product has been established. Whether or not a medicinal product is ultimately included in the SL is determined by the FOPH.

The evidence of cannabis's efficacy for medicinal purposes was long considered insufficient. On 30 April 2021, a Health Technology Assessment (HTA) report was published on behalf of the FOPH to provide additional information and to clarify the scientific evidence of the use of cannabis for medicinal purposes. However, the HTA report ultimately found no sufficient evidence for the efficacy of the use of medicinal cannabis. Therefore, an inclusion of medicinal products containing cannabis in the SL and the correlating reimbursement by the OKP is not possible under the general regime of reimbursement by the OKP.

By way of exemption, the reimbursement of a medicinal product not listed in the SL by the OKP is possible in case of hardship and upon request for cost approval by the treating physician. A case of hardship is defined as a case in which the use of the product is expected to provide a major therapeutic benefit against a disease that may be fatal for the insured person or result in severe and chronic health impairments, and no other effective and approved treatment method is available due to a lack of therapeutic alternatives.

The latest revision of the NarcA does not affect the current rules on reimbursement of medicinal products containing cannabis. Therefore, as was the case before the revision, the only way to obtain reimbursement by the OKP is by way of seeking reimbursement based on hardship.

Two-stage authorization procedure for the cultivation of cannabis

As a result of the removal of the ban on medicinal cannabis, a license from Swissmedic can be obtained for the cultivation of cannabis plants by passing the following two-stage authorization procedure:

  1. In a first step, the applicant must obtain an establishment license, which is granted under the following conditions:
  • The applicant is registered in the commercial register.
  • The correct storage of the controlled substance is ensured.
  • A person responsible for compliance with the NarcA is appointed.

Furthermore, the applicant must show that measures have been taken to provide sufficient protection against theft and to prevent the misuse of the plants.

  1. In a second step, the applicant must obtain an individual cultivation license, which is granted under the following conditions:
  • The applicant has obtained the above-mentioned establishment license.
  • The applicant has demonstrated that a system is in place that enables the traceability and quality of the substances supplied.
  • The applicant has submitted a written purchase agreement with a purchaser who is in possession of a corresponding establishment license.
  • The applicant has provided detailed information on the type of cultivation intended.

Once the applicant has obtained the individual cultivation license, it must comply with reporting obligations within 10 working days for each case.

Global context and outlook

There is little consistency among European countries when it comes to the use of cannabis as a medicinal product. By legalizing medicinal cannabis, Switzerland has followed the UK, the Netherlands, Italy and Germany, which already have systems in place that allow access to medical treatment with cannabis and, simultaneously, protect people by containing and combating the black market for cannabis. On the other hand, countries including Sweden, Latvia, Belgium and Albania strictly prohibit the use of medicinal cannabis while France, Ireland and Denmark are running trial periods for medicinal cannabis.

The potential for the emerging global market for cannabis-based medicines and supplements is estimated at USD 50 billion to several hundred billion US dollars. It is a complex market that is growing very fast, but the revision of the NarcA has created a clear route through the complexity for Swiss farmers and pharma pioneers looking to make sizeable profits by getting in early. This allows for a good opportunity for Swiss producers to serve a part of the rapidly developing world market. For many Swiss farmers, this could mean additional earnings of around CHF 10,000 per acre. As with any new change in law, legal uncertainty may arise.

* * * * *

Thanks to Tanya Adams and Anna Bachmann for supporting us in preparing this alert.

Copyright © 2024 Baker & McKenzie. All rights reserved. Ownership: This documentation and content (Content) is a proprietary resource owned exclusively by Baker McKenzie (meaning Baker & McKenzie International and its member firms). The Content is protected under international copyright conventions. Use of this Content does not of itself create a contractual relationship, nor any attorney/client relationship, between Baker McKenzie and any person. Non-reliance and exclusion: All Content is for informational purposes only and may not reflect the most current legal and regulatory developments. All summaries of the laws, regulations and practice are subject to change. The Content is not offered as legal or professional advice for any specific matter. It is not intended to be a substitute for reference to (and compliance with) the detailed provisions of applicable laws, rules, regulations or forms. Legal advice should always be sought before taking any action or refraining from taking any action based on any Content. Baker McKenzie and the editors and the contributing authors do not guarantee the accuracy of the Content and expressly disclaim any and all liability to any person in respect of the consequences of anything done or permitted to be done or omitted to be done wholly or partly in reliance upon the whole or any part of the Content. The Content may contain links to external websites and external websites may link to the Content. Baker McKenzie is not responsible for the content or operation of any such external sites and disclaims all liability, howsoever occurring, in respect of the content or operation of any such external websites. Attorney Advertising: This Content may qualify as “Attorney Advertising” requiring notice in some jurisdictions. To the extent that this Content may qualify as Attorney Advertising, PRIOR RESULTS DO NOT GUARANTEE A SIMILAR OUTCOME. Reproduction: Reproduction of reasonable portions of the Content is permitted provided that (i) such reproductions are made available free of charge and for non-commercial purposes, (ii) such reproductions are properly attributed to Baker McKenzie, (iii) the portion of the Content being reproduced is not altered or made available in a manner that modifies the Content or presents the Content being reproduced in a false light and (iv) notice is made to the disclaimers included on the Content. The permission to re-copy does not allow for incorporation of any substantial portion of the Content in any work or publication, whether in hard copy, electronic or any other form or for commercial purposes.